Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 11/20 | 0.70 |
| ▸ | MTTP | P55157 | 7/20 | 0.50 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6582536 | 1.00 | NPY2R (0.70) | NPY2RMTTPCCR3GAASMN1; SMN2 | |
| SCHEMBL2582758 | 0.92 | NPY2R (0.83) | NPY2RMTTPCCR3GAASMN1; SMN2 | |
| SCHEMBL13522056 | 0.92 | NPY2R (0.83) | NPY2RMTTPGAA | |
| SCHEMBL12174384 | 0.90 | NPY2R (0.69) | NPY2RMTTP | |
| SCHEMBL13522049 | 0.89 | NPY2R (0.65) | NPY2RMTTPCCR3 | |
| SCHEMBL12157791 | 0.89 | NPY2R (0.78) | NPY2RMTTPCCR3GAASMN1; SMN2 | |
| SCHEMBL12157814 | 0.89 | NPY2R (0.67) | NPY2RMTTP | |
| SCHEMBL12157792 | 0.88 | NPY2R (0.67) | NPY2RMTTP | |
| SCHEMBL12157816 | 0.88 | NPY2R (0.66) | NPY2RMTTPGAA | |
| SCHEMBL12174502 | 0.88 | NPY2R (0.70) | NPY2RMTTPCCR3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642378-B2 | Lipid lowering biphenylcarboxamides | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-05 | — | — | US | disclosed |
| US-7642378-B2 | Lipid lowering biphenylcarboxamides | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-05 | — | — | US | disclosed |
| US-7642378-B2 | Lipid lowering biphenylcarboxamides | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-05 | — | — | US | disclosed |
| US-20080081813-A1 | Lipid Lowering Biphenylcarboxamides | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081813-A1 | Lipid Lowering Biphenylcarboxamides | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081813-A1 | Lipid Lowering Biphenylcarboxamides | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-03 | — | — | US | disclosed |
| EP-1379515-B1 | LIPID LOWERING BIPHENYLCARBOXAMIDES | JANSSEN PHARMACEUTICA NV (BE) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081813-A1 | Lipid Lowering Biphenylcarboxamides | LIPC, PNLIP, LIPA | NPY2R 1487/4885MTTP 20/4885CCR3 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.